MedImmune Ventures, the corporate venturing unit of AstraZeneca, has helped Coferon, a US-based healthcare company, raise $12m.

The unit was joined in Coferon’s series B by venture firms Hatteras Venture Partners and Ascent Biomedical Ventures.

Dr. Colin Goddard, who had been acting as a part-time executive chairman for Coferon and was formerly chief executive of OSI Pharmaceuticals, before its $4 billion acquisition by Astellas Pharma in 2010, has becomeCoferon’s executive chairman.

Michael Gutch, managing director of MedImmune Ventures, said: “After…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?